

Figure 3. Invasive-Disease–free Survival and Overall Survival According to Menopausal Status.

Shown are the proportions of patients who were alive and free of invasive disease (Panels A and B) or alive with or without recurrence (Panels C and D) according to menopausal status (postmenopausal [defined as >5 years since menopause] vs. premenopausal, perimenopausal, or unknown). The I bars represent 95% confidence intervals.

effects. A full description of the adverse-event profile in this trial has been reported previously.[19] Confirmed osteonecrosis of the jaw occurred in 1.1% of patients who were treated with zoledronic acid, with an additional nine suspected cases. Resolution of osteonecrosis of the jaw was seen in some cases, but the observed frequency of this complication in our study was higher than that reported in other studies of zoledronic acid in patients receiving adjuvant therapy.[8,20] This discrepancy presumably reflects the more intensive schedule of zoledronic acid and greater use of chemotherapy in our study. On the positive side, zoledronic acid was associated with a reduction in rates of fracture, particularly among patients who had a disease recurrence.

10.1056/NEJMoa1105195 NEJM.ORG

The New England Journal of Medicine
Downloaded from nejm.org on September 25, 2011. For personal use only. No other uses without permission.
Copyright © 2010 Massachusetts Medical Society. All rights reserved.